These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 16317671

  • 1. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M.
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [Abstract] [Full Text] [Related]

  • 2. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 3. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [Abstract] [Full Text] [Related]

  • 4. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [Abstract] [Full Text] [Related]

  • 5. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [Abstract] [Full Text] [Related]

  • 6. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA.
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

  • 8. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [Abstract] [Full Text] [Related]

  • 9. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [Abstract] [Full Text] [Related]

  • 10. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.
    N Engl J Med; 2008 Dec 04; 359(23):2442-55. PubMed ID: 19052126
    [Abstract] [Full Text] [Related]

  • 11. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug 04; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J.
    J Viral Hepat; 2008 May 04; 15(5):392-8. PubMed ID: 18221300
    [Abstract] [Full Text] [Related]

  • 13. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T.
    Hepatology; 2006 Aug 04; 44(2):318-25. PubMed ID: 16871563
    [Abstract] [Full Text] [Related]

  • 14. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW.
    Zhonghua Nei Ke Za Zhi; 2007 Apr 04; 46(4):294-7. PubMed ID: 17637268
    [Abstract] [Full Text] [Related]

  • 15. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q, Gong ZJ, Hu DF.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul 04; 17(7):515-9. PubMed ID: 19912686
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Xu Z, Chen LB, Cao H, Shu X, Xu QH, Li G, Xie QF.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun 04; 24(3):224-6. PubMed ID: 21186534
    [Abstract] [Full Text] [Related]

  • 17. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.
    Scotto G, Palumbo E, Fazio V, Tartaglia A, Saracino A, Angarano G.
    New Microbiol; 2005 Jul 04; 28(3):193-7. PubMed ID: 16240690
    [Abstract] [Full Text] [Related]

  • 18. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.
    Arab J Gastroenterol; 2014 Mar 04; 15(1):1-5. PubMed ID: 24630505
    [Abstract] [Full Text] [Related]

  • 19. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.
    Antivir Ther; 2012 Mar 04; 17(4):701-9. PubMed ID: 22358132
    [Abstract] [Full Text] [Related]

  • 20. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM, Park JY, Kim DY, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH.
    Antivir Ther; 2010 Mar 04; 15(2):235-41. PubMed ID: 20386079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.